Skip to Content

Capreomycin Pregnancy and Breastfeeding Warnings

Capreomycin is also known as: Capastat, Capastat Sulfate

Medically reviewed on March 6, 2018

Capreomycin Pregnancy Warnings

Animal studies have revealed evidence of teratogenicity at doses of at least 3.5 times the recommended human dose. Some animal models have reported wavy ribs at doses of at least 50 mg/kg. There are no controlled data in human pregnancy.

US FDA pregnancy category C: Animal reproduction studies have shown an adverse effect on the fetus and there are no adequate and well-controlled studies in humans, but potential benefits may warrant use of the drug in pregnant women despite potential risks.

This drug should not be used during pregnancy unless the benefit outweighs the risk to the fetus.

US FDA pregnancy category: C

See references

Capreomycin Breastfeeding Warnings

Caution is recommended.

Excreted into human milk: Unknown
Excreted into animal milk: Data not available

Comment: Some experts state that use of this drug is not a reason to discontinue breastfeeding.

See references

References for pregnancy information

  1. "Product Information. Capastat Sulfate (capreomycin)." Dura Pharmaceuticals, San Diego, CA.

References for breastfeeding information

  1. United States National Library of Medicine "Toxnet. Toxicology Data Network. Available from: URL: http://toxnet.nlm.nih.gov/cgi-bin/sis/htmlgen?LACT." ([cited 2013 -]):
  2. "Product Information. Capastat Sulfate (capreomycin)." Dura Pharmaceuticals, San Diego, CA.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide